Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | CA2 | P00918 | 2/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | PPARA | Q07869 | 9/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | PPARG | P37231 | 3/20 | 0.50 |
| ▸ | FABP2 | P12104 | 2/20 | 0.50 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1306107 | 0.88 | PPARA (0.60) | PPARAMAPTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9303086 | 0.85 | MAPT (0.57) | CA1CA2CA12CA9PPARA | |
| SCHEMBL16303954 | 0.85 | PPARA (0.61) | PPARAMAPTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL805971 | 0.85 | PPARA (0.61) | PPARAMAPTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1304565 | 0.84 | EPHX1 (0.59) | CA1CA2CA12CA9PPARA | |
| SCHEMBL1305530 | 0.84 | PPARA (0.55) | CA1CA2CA12CA9PPARA | |
| SCHEMBL1305000 | 0.84 | MAPT (0.68) | CA2PPARAMAPTCYP1A2CYP3A4 | |
| SCHEMBL9303663 | 0.82 | MEN1 (0.57) | CA1CA2CA12CA9PPARA | |
| SCHEMBL9131125 | 0.82 | PPARA (0.52) | CA1CA2CA12CA9PPARA | |
| SCHEMBL1304908 | 0.82 | MEN1 (0.62) | CA1CA2CA12CA9PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048896-B2 | Inhibit nonenzymatic formation of advanced glycation end-products (AGE) using e.g. aminoguanidine, OPB-9195 [(+/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yla cetanilide], pyridoxamine, antioxidants, alagebrium, antihypertensives, angiotensin-converting enzyme inhibitors | Cell Viable Corporation (US) | 2011-11-01 | — | — | US | claimed |
| EP-1592435-A4 | OPHTHALMIC FORMULATION FOR THE PREVENTION AND TREATMENT OF OCULAR CONDITIONS | CHAKSHU RES INC (US) | 2008-01-23 | — | — | EP | claimed |
| EP-1592435-A1 | OPHTHALMIC FORMULATION FOR THE PREVENTION AND TREATMENT OF OCULAR CONDITIONS | Chakshu Research, Inc. (US) | 2005-11-09 | — | — | EP | claimed |
| US-20040137068-A1 | Ophthalmic formulation for the prevention and treatment of adverse ocular conditions, particularly those associated with the aging eye | LIVIONEX INC. | 2004-07-15 | — | — | US | claimed |
| WO-2004058289-A1 | OPHTHALMIC FORMULATION FOR THE PREVENTION AND TREATMENT OF OCULAR CONDITIONS | CHAKSHU RESEARCH, INC. (US) | 2004-07-15 | — | — | WO | claimed |
| EP-1165064-B1 | NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) | HOPE CITY (US) | 2004-02-25 | — | — | EP | claimed |
| US-6337350-B1 | CROSSLINKING INHIBITION OF PROTEINS | CITY OF HOPE | 2002-01-08 | — | — | US | claimed |
| EP-1165064-A2 | NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) | City of Hope (US) | 2002-01-02 | — | — | EP | claimed |
| WO-2000059875-A2 | NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) | CITY OF HOPE (US) | 2000-10-12 | — | — | WO | claimed |
| US-8053449-B2 | Method for inhibiting AGE complex formation | Cell Viable Corporation (US) | 2011-11-08 | — | — | US | disclosed |
| US-8048896-B2 | Inhibit nonenzymatic formation of advanced glycation end-products (AGE) using e.g. aminoguanidine, OPB-9195 [(+/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yla cetanilide], pyridoxamine, antioxidants, alagebrium, antihypertensives, angiotensin-converting enzyme inhibitors | Cell Viable Corporation (US) | 2011-11-01 | — | — | US | disclosed |
| EP-1972344-A1 | Ophthalmic formulation for the prevention and treatment of ocular conditions | Chakshu Research, Inc. (US) | 2008-09-24 | — | — | EP | disclosed |
| EP-1906918-A2 | TREATMENT OF CONDITIONS ASSOCIATED WITH THE PRESENCE OF MACROMOLECULAR AGGREGATES, PARTICULARLY OPHTHALMIC DISORDERS | Chakshu Research, Inc. (US) | 2008-04-09 | — | — | EP | disclosed |
| EP-1904108-A2 | FORMULATION AND METHOD FOR ADMINISTRATION OF OPHTHALMOLOGICALLY ACTIVE AGENTS | Chakshu Research, Inc. (US) | 2008-04-02 | — | — | EP | disclosed |
| US-20040137068-A1 | Ophthalmic formulation for the prevention and treatment of adverse ocular conditions, particularly those associated with the aging eye | LIVIONEX INC. | 2004-07-15 | — | — | US | disclosed |
| WO-2004058289-A1 | OPHTHALMIC FORMULATION FOR THE PREVENTION AND TREATMENT OF OCULAR CONDITIONS | CHAKSHU RESEARCH, INC. (US) | 2004-07-15 | — | — | WO | disclosed |
| EP-1165064-B1 | NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) | HOPE CITY (US) | 2004-02-25 | — | — | EP | disclosed |
| US-6337350-B1 | CROSSLINKING INHIBITION OF PROTEINS | CITY OF HOPE | 2002-01-08 | — | — | US | disclosed |
| EP-1165064-A2 | NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) | City of Hope (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000059875-A2 | NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) | CITY OF HOPE (US) | 2000-10-12 | — | — | WO | disclosed |